Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of POLLUX

Authors :: Dimopoulos, M.A. San-Miguel, J. Belch, A. White, D. Benboubker, L. Cook, G. Leiba, M. Morton, J. Joy Ho, P. Kim, K. Takezako, N. Moreau, P. Kaufman, J.L. Sutherland, H.J. Lalancette, M. Magen, H. Iida, S. Kim, J.S. Miles Prince, H. Cochrane, T. Oriol, A. Bahlis, N.J. Chari, A. O’Rourke, L. Wu, K. Schecter, J.M. Casneuf, T. Chiu, C. Soong, D. Kate Sasser, A. Khokhar, N.Z. Avet-Loiseau, H. Usmani, S.Z.
Publication Year :: 2018
Abstract: In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/ dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow up and include the effect on minimal residual disease and in clinically relevant subgroups. After 25.4 months of follow up, daratumumab plus lenalidomide/dexamethasone prolonged progression-free survival versus lenalidomide/dexamethasone alone (median not reached vs. 17.5 months; hazard ratio, 0.41; 95% confidence interval, 0.31-0.53; P12 and ≤12 months and >6 and ≤6 months. No new safety signals were observed. In relapsed/refractory multiple myeloma patients, daratumumab plus lenalidomide/dexamethasone continued to improve progression-free survival and deepen responses versus lenalidomide/dexamethasone. © 2018 Ferrata Storti Foundation.

Tools